

BOLOGNA, W. et al  
Serial No. unknown


REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



Arthur R. Crawford  
Reg. No. 25,327

ARC:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

BOLOGNA, W. et al.  
Serial No. unknown

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Page 1, before the first line, insert as a separate paragraph:

This application is the US national phase of international application

PCT/EP00/09708 filed 4 October 2000, which designated the US.

**IN THE CLAIMS**

11. The composition of ~~either of claims 5-or-9~~ wherein the agonist is used to treat endometriosis.
  
12. The composition of ~~either of claims 5-or-9~~ wherein the agonist is used to treat infertility or to improve fertility.
  
20. The method of ~~either of claims 15-or-19~~, wherein the composition is administrated every 12 to 96 hours.
  
21. The method of ~~either of claims 15-or-19~~, wherein composition is administrated twice weekly.
  
22. Te method of ~~either of claims 15-or-19~~, wherein the composition further comprises a tablet.

BOLOGNA, W. et al.

Serial No. unknown

25. Use accordingly to claim 23-~~or~~24 wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the  $\beta$ -adrenergic agonist per dose.

26. Use according to ~~any one of~~ claim 23-~~to~~25 wherein the  $\beta$ -adrenergic agonist is terbutaline.

27. Use according to ~~any one of~~ claims 23-~~to~~26 wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the  $\beta$ -adrenergic agonist per dose.

28. Use according to ~~any one of~~ claims 23-~~to~~27 wherein the bioadhesive carrier comprises a cross-linked water-insoluble but water-swellable polycarboxylic acid polymer.

32. Use according to claim 30-~~or~~31 wherein the medicament is for administration every 12 to 96 hours.

33. Use according to claim 30-~~or~~31 wherein the medicament is for administration twice weekly.

34. Use according to ~~any one of~~ claims 23-~~to~~33 wherein the medicament avoids detrimental blood levels of the  $\beta$ -adrenergic agonist.

**BOLOGNA, W. et al.**  
Serial No. unknown.

35. Use according to any one of claims 23 to 34 wherein the medicament is presented in tablet form.